Please check your internet connection and try again.
# Urimax (Tamsulosin)
## Overview
Tamsulosin is a selective α1-adrenoceptor antagonist that preferentially binds to α1A receptors found in the prostate and bladder neck. By relaxing smooth muscle tone, it facilitates urinary flow in conditions characterized by obstruction.
## Primary Indications
* Benign Prostatic Hyperplasia (BPH)
* Off-label: Ureteral stone expulsion (Medical Expulsive Therapy)
## Adult Dosing
* **BPH:** 0.4 mg orally once daily, taken 30 minutes after the same meal each day.
* **Maximum Dose:** 0.8 mg daily. If no response after 2–4 weeks at 0.4 mg, the dose may be increased to 0.8 mg.
## Pediatric Dosing
* **Not indicated/Not established:** Tamsulosin is not approved for pediatric use. Use in children is generally off-label (e.g., for neurogenic bladder) and requires specialized pediatric urological supervision. Dosing is highly variable per institutional protocol; standard adult dosing should never be assumed.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment necessary.
* **Hepatic Impairment:** Use caution in severe hepatic impairment (Child-Pugh class C); no specific dose reduction protocols are established.
* **CYP3A4/2D6 Inhibitors:** Avoid or limit use when administered with potent inhibitors.
## Contraindications
* Known hypersensitivity (e.g., serious skin reactions or angioedema) to tamsulosin.
* Concomitant use of potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin).
## Adverse Effects
* **Common:** Dizziness, headache, abnormal ejaculation (retrograde), rhinitis, and orthostatic hypotension.
* **Serious:** Syncope (especially with the first dose), intraoperative floppy iris syndrome (IFIS) during cataract surgery, priapism, and severe allergic reactions.
## Key Drug Interactions
* **Antihypertensives/PDE5 Inhibitors:** Risk of additive hypotensive effects; monitor closely for symptomatic orthostasis.
* **Potent CYP3A4 Inhibitors:** May significantly increase tamsulosin plasma concentrations.
* **CYP2D6 Inhibitors:** Use caution in "poor metabolizers" or patients taking strong inhibitors (e.g., fluoxetine, paroxetine) as this increases exposure.
## Monitoring
* Monitor blood pressure during dose initiation or titration to evaluate for orthostatic hypotension.
* Assess urinary symptom improvement (e.g., IPSS scores).
* Screen for history of cataract surgery or planning for surgery due to IFIS risk.
## Clinical Pearls
* **Administration:** Must be taken on a consistent schedule relative to meals (30 minutes after the same meal). Taking it on an empty stomach alters absorption profiles and may increase side effects.
* **Surgery:** If the patient is scheduled for cataract or glaucoma surgery, inform the ophthalmologist of current or prior tamsulosin use, as it significantly complicates surgical management.
* **Syncope:** Advise patients to rise slowly from a sitting or lying position, especially during the first few days of therapy.
***
*Disclaimer: This information is for educational purposes only. Clinical practice protocols vary. Always verify current prescribing information, contraindications, and drug-drug interactions via institutional guidelines or official FDA-approved package inserts before prescribing or dispensing.*
